Ph.D., Michigan State University
My laboratory is interesting in finding novel target genes of prevalent cancers in Taiwan for clinical applications. We apply cutting-edge approaches such as genomics, bioinformatics, epigenomics and molecular cell biology to dissect tumorigenic pathways, study molecular mechanisms of tumor progression and develop therapeutic strategies. We recently established a protocol to analyze copy number alterations (CNA) in cancer genomes using high density SNP arrays with non-paired reference genomes and to demonstrate common altered target genes in human hepatocellular carcinoma (HCC). We applied integrated genomic approaches to reveal genome-wide alterations of cancer genomes and established comprehensive cancer databases including TPMD, OncoDB.HCC, OncoDB.NSCLC, and IGRhCellID for various applications including cell authenticity, selection of cell line with designated genetic background, and detection of common altered loci and genes in cancer genome. Other projects are studies of (1) tumorigenic mechanisms of aberrant cancer genes involved in 13q12.1 homozygous deleted region; (2) low toxic combination cancer therapy targeting epigenetically activated cancer metastasis genes; (3) integrated genomic and bioinformatic approaches for revealing cancer targets for diagnosis and therapy in human HCC and lung cancers; (4) molecular mechanisms of novel somatic mutations involved in tumor pathogenesis; and (5) molecular mechanisms of altered translational machinery especially EIF3 proteins in tumorigenesis.
我們以基因體、生物資訊、表基因體、分子及細胞生物等技術，研究台灣常見癌症新穎基因之致癌途逕、分子機轉及治療策略。我們以SNP晶片，偵測癌症基因體套數變異、發掘新穎致癌基因。我們整合不同癌症變異數據，建立全基因體癌症資料庫TPMD, OncoDB.HCC, IGRhCellID 和 OncoDB. NSCLC。